Literature DB >> 8375525

Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus.

W H Kutteh1, E C Lyda, S M Abraham, M C Wacholtz.   

Abstract

OBJECTIVE: To analyze the pregnancy history in relation to the presence or absence of anticardiolipin antibodies in women who had been diagnosed with systemic lupus erythematosus (SLE).
DESIGN: One-hundred twenty-five women of reproductive age who were diagnosed with SLE and attended the Lupus Clinic at Parkland Memorial Hospital or Southwestern Medical Center were selected for this study. A retrospective review of patient histories, including anticardiolipin antibody test results and pregnancy histories, was conducted. Women who had therapeutic pregnancy terminations were excluded from this study. A chi 2 analysis was used to evaluate the significance of the data.
RESULTS: In women with SLE of childbearing age with anticardiolipin antibodies, a 39% pregnancy loss rate occurred, compared with an 11% loss rate in anticardiolipin antibody-negative women. In women with at least two pregnancies who had anticardiolipin antibodies, 27% experienced two or more losses, whereas only 3% of antibody-negative women had recurrent pregnancy loss.
CONCLUSION: We conclude that women with SLE and the presence of anticardiolipin antibodies are at increased risk for pregnancy loss.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375525     DOI: 10.1016/s0015-0282(16)56159-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

Review 1.  Lupus pregnancies and neonatal lupus.

Authors:  M D Lockshin
Journal:  Springer Semin Immunopathol       Date:  1994

2.  Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group.

Authors:  C Sachse; K Lüthke; K Hartung; M Fricke; B Liedvogel; J R Kalden; H H Peter; H J Lakomek; E Henkel; H Deicher
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.